Plus Therapeutics (PSTV) Expected to Announce Quarterly Earnings on Tuesday

Plus Therapeutics (NASDAQ:PSTV) is anticipated to release its earnings data before the market opens on Tuesday, March 4th. Analysts expect Plus Therapeutics to post earnings of ($0.51) per share and revenue of $1.19 million for the quarter.

Plus Therapeutics Stock Performance

NASDAQ:PSTV opened at $1.14 on Tuesday. Plus Therapeutics has a 52 week low of $0.93 and a 52 week high of $2.67. The firm has a 50-day moving average price of $1.18 and a two-hundred day moving average price of $1.31. The firm has a market cap of $6.72 million, a price-to-earnings ratio of -0.45 and a beta of 0.70.

Wall Street Analysts Forecast Growth

PSTV has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Plus Therapeutics in a research report on Tuesday, November 26th. Ascendiant Capital Markets lowered their target price on Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a research note on Monday, December 9th.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.